{"id":"NCT01683266","sponsor":"Sanofi","briefTitle":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus","officialTitle":"A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and LantusÂ® Injected in the Morning or Evening in Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09","primaryCompletion":"2013-09","completion":"2014-03","firstPosted":"2012-09-11","resultsPosted":"2015-04-23","lastUpdate":"2015-06-24"},"enrollment":549,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"HOE901-U300 (Insulin glargine new formulation)","otherNames":[]},{"type":"DRUG","name":"Lantus (Insulin glargine)","otherNames":[]}],"arms":[{"label":"HOE901-U300","type":"EXPERIMENTAL"},{"label":"Lantus","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\n* To compare the efficacy of a new formulation of insulin glargine and Lantus (overall, regardless the injection time) in terms of change of HbA1c from baseline to endpoint (scheduled Month 6) in participants with type 1 diabetes mellitus\n\nSecondary Objective:\n\n* To compare HOE901-U300 and Lantus when given in the morning or in the evening in terms of:\n* Change of HbA1c from baseline to endpoint (scheduled Month 6)\n* Change from baseline to endpoint (Month 6) in fasting plasma glucose (FPG), plasma glucose prior to injection of study drug, plasma glucose at 03:00 hours, mean plasma glucose (8-point profiles), glucose variability, treatment satisfaction and health related quality of life in participants with Type 1 Diabetes Mellitus (T1DM)\n* Reaching target HbA1c values and controlled plasma glucose (all and reaching target without hypoglycemia)\n* Frequency of occurrence and diurnal distribution of hypoglycemia by category of hypoglycemia (symptomatic, asymptomatic, nocturnal, severe, probable and relative)\n* Safety and tolerability of HOE901-U300 including development of anti-insulin antibody (AIAs) during the 12-month study period","primaryOutcome":{"measure":"Change In HbA1c From Baseline to Month 6 Endpoint","timeFrame":"Baseline, Month 6","effectByArm":[{"arm":"HOE901--U300","deltaMin":-0.4,"sd":0.051},{"arm":"Lantus","deltaMin":-0.44,"sd":0.051}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":8},"locations":{"siteCount":147,"countries":["United States","Canada","Czechia","Denmark","Estonia","Finland","Hungary","Japan","Latvia","Netherlands","Puerto Rico","Romania","Sweden"]},"refs":{"pmids":["28661585"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":274},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Influenza","Headache","Sinusitis"]}}